Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells
Open Orphan PLC (ORPH.L) £5.7m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Vela Technologies (VELA.L) Update re. Aeristech
The Board of Vela notes the announcement by Sprintex (ASX: SIX) of its collaboration agreement with Aeristech Limited (“Aeristech”) which will facilitate Sprintex’s penetration into the high-growth and lucrative hydrogen
Vela Technologies (VELA.L) Update re. St George Street Capital Holding
The Board of Vela is pleased to announce that the Company’s joint broker, Peterhouse Capital Limited, has today placed the entirety of St. George Street Capital’s (“SGSC”) 1,100,000,000 shares with
Omega Diagnostics Gp (ODX.L) AGM Statement
Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, will hold its Annual General Meeting (‘AGM’) today at 11am at Omega
N4 Pharma PLC (N4P.L) Operations Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its current
Poolbeg Pharma PLC (POLB.L) September and October Investor conferences
Poolbeg Pharma to present at investor conferences
NASDAQ:TLSA | LSE:TILS: Foralumab Now in CAR T
On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the exploration and development of foralumab as a lymphodepletion agent to
Yourgene Health PLC (YGEN.L) Re DHSC contract to support COVID-19 surge testing
Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the
Open Orphan PLC (ORPH.L) Notice of Interim Results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that its
Vela Technologies (VELA.L) Update re. St George Street Capital COVID-19 trial
Further to the update released by Vela on 6 September 2021, the Board of Vela has been informed by St George Street Capital (“SGSC”) that, following receipt of the final
